Entheon Biomedical Income Statement

Financials in millions CAD. Fiscal year is December - November.

Millions CAD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 28, 2026	Nov '25 Nov 30, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021
Revenue	-	-	-	0.25	0.19	-
Revenue Growth (YoY)	-	-	-	31.97%	-	-
Gross Profit	-	-	-	0.25	0.19	-
Selling, General & Admin	0.28	0.33	0.33	0.56	2.5	4.45
Research & Development	-	-	-	-	1.2	1.21
Operating Expenses	0.29	0.33	0.33	0.56	3.79	8.21
Operating Income	-0.29	-0.33	-0.33	-0.31	-3.6	-8.21
Interest & Investment Income	0.01	0.01	0.02	0.01	0	0.01
Currency Exchange Gain (Loss)	-0	-0	-0	-0	0.02	0
Other Non Operating Income (Expenses)	0	-	-	0	0.25	-0
EBT Excluding Unusual Items	-0.28	-0.32	-0.32	-0.3	-3.33	-8.2
Gain (Loss) on Sale of Investments	-	-	-	0	-0.07	0.21
Gain (Loss) on Sale of Assets	-	-	-	-	1.34	-
Pretax Income	-0.28	-0.32	-0.32	-0.3	-2.06	-8
Earnings From Continuing Operations	-0.28	-0.32	-0.32	-0.3	-2.06	-8
Earnings From Discontinued Operations	-	-	-	-	-6.46	-0.89
Net Income	-0.28	-0.32	-0.32	-0.3	-8.52	-8.89
Net Income to Common	-0.28	-0.32	-0.32	-0.3	-8.52	-8.89
Shares Outstanding (Basic)	16	13	8	6	6	5
Shares Outstanding (Diluted)	16	13	8	6	6	5
Shares Change (YoY)	67.81%	73.25%	30.96%	-	8.85%	97.83%
EPS (Basic)	-0.02	-0.02	-0.04	-0.05	-1.44	-1.64
EPS (Diluted)	-0.02	-0.02	-0.04	-0.05	-1.44	-1.64
Free Cash Flow	-0.26	-0.31	-0.36	-0.36	-1.95	-5.33
Free Cash Flow Per Share	-0.02	-0.02	-0.05	-0.06	-0.33	-0.98
Gross Margin	-	-	-	100.00%	100.00%	-
Operating Margin	-	-	-	-124.96%	-1898.18%	-
Profit Margin	-	-	-	-119.85%	-4492.23%	-
Free Cash Flow Margin	-	-	-	-143.79%	-1030.49%	-
EBITDA	-	-	-	-	-3.6	-8.18
D&A For EBITDA	-	-	-	-	0	0.04
EBIT	-0.29	-0.33	-0.33	-0.31	-3.6	-8.21
EBIT Margin	-	-	-	-124.96%	-	-
Revenue as Reported	-	-	-	0.25	0.19	-

Updated Feb 28, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.